Analyst Price Target is $7.00
▲ +366.67% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Bolt Biotherapeutics in the last 3 months. The average price target is $7.00, with a high forecast of $13.00 and a low forecast of $3.00. The average price target represents a 366.67% upside from the last price of $1.50.
Current Consensus is
Hold
The current consensus among 3 investment analysts is to hold stock in Bolt Biotherapeutics. This rating has held steady since November 2022, when it changed from a Buy consensus rating.
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
Read More